PROMAXX® inhaled insulin: Safe and efficacious administration with a commercially available dry powder inhaler

Diabetes, Obesity and Metabolism

Volumn 11, Issue 5, 2009, Pages 455-459

  Heise, T ^a   Brugger, A ^b   Cook, C ^b   Eckers, U ^a   Hutchcraft, A ^b   Nosek, L ^a   Rave, K ^a   Troeger, J ^b   Valaitis, P ^b   White, S ^b   Heinemann, Lutz ^a  

^a Profil Institute for Metabolic Research   (Germany)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Absorption; Diabetes; Glucose; Inhaled insulin; Microspheres; PROMAXX

Indexed keywords

ACTAPID HM; MICROSPHERE; NEUTRAL INSULIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; C PEPTIDE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPNEA; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; GERMANY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; C-PEPTIDE; CROSS-OVER STUDIES; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MICROSPHERES; NEBULIZERS AND VAPORIZERS; TREATMENT OUTCOME;

EID: 65449154325     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00961.x     Document Type: Article

References (7)

1. White S, Brown L, McGeehan J, Hogeland K, Brugger A, Troeger J. The science and technology of the PROMAXX biotechnology platform. In: Respiratory Drug Delivery Europe 2007; 51-58. Virginia Commonwealth University, Richmond, VA, USA.
2. Heinemann L, Heise T. Current status of the development of inhaled insulin. Br J Diabetes Vasc Dis 2004; 4: 295-301.
3. Kim D, Mudaliar S, Chinnapongse S et al. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003; 26: 2842-2847.
4. Clemens AH, Hough DL, D'OrazIo PA. Development of the Biostator Glucose Clamping Algorithm. Clin Chem 1982; 28: 1899-1904.
5. SAS OnlineDoc® Version Nine. Cary, NC: SAS Institute Inc., Available from URL: http://support.sas.com/documentation/onlinedoc/ sas9doc.html
6. Sebti T, Pilcer G, Van Gansbeke B et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm 2006; 64: 26-32.
7. Heise T, Kapitza C, Hompesch M, Heinemann L. Inhaled insulin as alternative delivery system for subjects with diabetes - a literature review. Av Diabetol 2005; 21: 91-102.